Announced That Gregory Spear Highlights the Following Stocks: Myriad GeneticsCHICAGO--(BUSINESS WIRE)--March 20, 2006--Gregory Spear explains that the market is once again celebrating the end of the Federal Reserve rate hike scenario. Learn about Myriad Genetics (Nasdaq:MYGN), Dynamic Materials (Nasdaq:BOOM), Flextronic International (Nasdaq:FLEX), Marathon Oil Corporation (NYSE:MRO) and Cummins Inc. (NYSE:CMI). Gregory Spear is the editor of The Spear Report newsletter. Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84
Highlights from the March 17 Featured Expert column by Gregory Spear include:
A sampling of profiled stocks:
Myriad Genetics (Nasdaq:MYGN) is a biotech company that is developing Flurizan, a therapeutic drug for the treatment of Alzheimer's disease. Flurizan is the first in a new class of drug candidates known as Selective Amyloid beta-42 Lowering Agents (SALAs). Abbreviated "Abeta42," this compound is the primary constituent of senile plaque that accumulates in the brain of patients with Alzheimer's disease. Most genetic mutations that cause early-onset Alzheimer's disease appear to do so by increasing production of Abeta42, which then causes neuronal damage. MYGN grew revenues 65% in 2005 to $80 million, posting a net loss of about $40 million. Cash on hand totals over $200 million, which is plenty to survive. Technically, a monthly chart of the stock shows a solid basing pattern and a new uptrend in progress.
Dynamic Materials (Nasdaq:BOOM) began over 30 years ago as an explosive metal forming business for the aerospace industry. Subsequently, the company licensed metal cladding technology from Dupont and eventually acquired Dupont's metal cladding business, as well as several other competitors in the U.S. and eventually in Europe. Explosion-welded clad metal is primarily used in the construction of large industrial equipment involving high pressures and temperatures, along with a requirement for corrosion-resistance. The company has operations in Pennsylvania, France and Sweden, and is 55% owned by SNPE, a French government-owned defense contractor. BOOM showed up on the radar of stock traders and investors in early 2005. Sales for that year grew 46% to $79 million and the company's EPS spiked 120% to $0.86 per share with improved margins, as well.
Highlights from the March 17 Featured Expert column by Gregory Spear include:
A sampling of profiled stocks:
Myriad Genetics (Nasdaq:MYGN) is a biotech company that is developing Flurizan, a therapeutic drug for the treatment of Alzheimer's disease. Flurizan is the first in a new class of drug candidates known as Selective Amyloid beta-42 Lowering Agents (SALAs). Abbreviated "Abeta42," this compound is the primary constituent of senile plaque that accumulates in the brain of patients with Alzheimer's disease. Most genetic mutations that cause early-onset Alzheimer's disease appear to do so by increasing production of Abeta42, which then causes neuronal damage. MYGN grew revenues 65% in 2005 to $80 million, posting a net loss of about $40 million. Cash on hand totals over $200 million, which is plenty to survive. Technically, a monthly chart of the stock shows a solid basing pattern and a new uptrend in progress.
Dynamic Materials (Nasdaq:BOOM) began over 30 years ago as an explosive metal forming business for the aerospace industry. Subsequently, the company licensed metal cladding technology from Dupont and eventually acquired Dupont's metal cladding business, as well as several other competitors in the U.S. and eventually in Europe. Explosion-welded clad metal is primarily used in the construction of large industrial equipment involving high pressures and temperatures, along with a requirement for corrosion-resistance. The company has operations in Pennsylvania, France and Sweden, and is 55% owned by SNPE, a French government-owned defense contractor. BOOM showed up on the radar of stock traders and investors in early 2005. Sales for that year grew 46% to $79 million and the company's EPS spiked 120% to $0.86 per share with improved margins, as well.
posted by Valery Yermalitsky at
5:16 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home